Anika Therapeutics (ANIK) Assets Average (2011 - 2026)

Anika Therapeutics (ANIK) has 16 years of Assets Average data on file, last reported at $184.8 million in Q1 2026.

• Assets Average for Q1 2026 came in at $184.8 million, down 6.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.8 million (down 6.02% YoY), and the FY2025 annual result was $196.5 million, down 16.98% from the prior year.
• Assets Average eased to $184.8 million in Q1 2026 per ANIK's latest filing, from $189.9 million in the prior quarter.
• Over five years, Assets Average peaked at $350.9 million in Q3 2022 and troughed at $184.8 million in Q1 2026.
• A 5-year average of $273.1 million and a median of $267.2 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average decreased 0.23% in 2023, then retreated 28.14% in 2025.
• A 5-year view of Assets Average shows it stood at $348.4 million in 2022, then retreated by 14.07% to $299.4 million in 2023, then slipped by 27.5% to $217.1 million in 2024, then slipped by 12.54% to $189.9 million in 2025, then decreased by 2.65% to $184.8 million in 2026.
• Business Quant data shows ANIK's Assets Average at $184.8 million in Q1 2026, $189.9 million in Q4 2025, and $188.6 million in Q3 2025.